-
2023-508476-11-00
1
Adenoid cystic carcinoma (ACC)
-
2024-516182-37-01
4
Maintenance treatment in patients with locally advanced/metastatic uro
-
2024-517621-54-00
5
High-risk non-muscle invasive bladder cancer (NMIBC) after transurethr
-
2024-519246-75-01
4
Patients With Muscle-Invasive Bladder Cancer
-
2024-519624-24-00
4
HER3-mutant and HER2-not amplified metastatic breast cancer
-
2024-519786-22-01
9
metastatic non-small cell lung cancer (NSCLC)
-
2024-520045-23-00
4
Kidney cancer
-
2025-521199-80-00
4
Patients with previously untreated symptomatic chronic lymphocytic leu
-
2025-521221-32-00
5
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2025-521587-35-00
5
Metastatic colorectal cancer
-
2025-521619-37-00
5
Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to r
-
2025-521909-40-00
4
Patients with metastatic or locally advanced HER2-low triple-negative
-
2025-521982-29-00
4
Adult patients with advanced hormone receptor positive (HR+), HER2- br
-
2025-522655-26-00
4
METAREM:Patients with advanced cancer, as defined as unresectable loca
-
2025-523586-18-00
5
Non-Small Cell Lung Cancer
-
2025-523683-20-00
4
Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2025-522996-27-00
5
2026-05-05
recurrent and/or metastatic squamous cell carcinoma of the head and ne
-
2025-523742-27-00
9
2026-04-28
Advanced solid tumors
-
2025-521884-12-00
5
2026-03-19
First line triple-negative breast cancer (TNBC)
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2024-514327-42-00
4
2025-12-18
Advanced neuroendocrine carcinomas (NECs) of the digestive system or u
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2023-508056-19-00
5
2025-10-02
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P